### U.S. PRODUCERS' QUESTIONNAIRE

#### PERSULFATES FROM CHINA

This questionnaire must be received by the Commission by no later than October 21, 2013

See page 5 of the Instruction Booklet for filing instructions.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its review of the antidumping duty order concerning persulfates from China (Inv. No. 731-TA-749 (Third Review)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your firm's possession (19 U.S.C. § 1333(a)).

Address						
City		State	Zip Code	e		
World Wide Web ad	dress					
Has your firm produced	persulfates (as defined in the	e instruction bo	ooklet) at any	time since Janu	uary 1, 2007?	
NO (Sign the	certification below and promptl	ly return only this	s page of the qu	estionnaire to th	ne Commission)	1
	instruction booklet carefully, carries to the Commission so as to				n the entire	
	ire via the U.S. Interna nk: https://dropbox.usito					
that the information house		IFICATION		and connect to	to the heat of r	ny knowlede
ef and understand that the ns of this certification I of tion provided in this que, ed by the Commission on to wledge that information so sion, its employees, and co ning the records of this pro- ings relating to the progra- personnel will sign non-d	in supplied in response to the information submitted is surely also grant consent for the stionnaire and throughout the same or similar merchant ontract personnel who are occeeding or related proceedings and operations of the Conscioure agreements.	nis questionnainabject to audit of Commission, of this proceeding dise.  The acting in the of the commission pure commission commission pure commission c	re is complete and verification and its emplo ag in any oth and through capacity of C this informati	on by the Combyees and conter import-injustion out this procession endings. C. Appendings.	mission.  tract personn  try proceeding  teding may be  nployees, for o  ed, or in intern	el, to use th gs or review e used by th developing o nal audits an
ef and understand that the  ns of this certification I of  tion provided in this que,  ed by the Commission on to  wledge that information s  sion, its employees, and of  ning the records of this pro-  tings relating to the progra	in supplied in response to the information submitted is surely also grant consent for the stionnaire and throughout the same or similar merchant cubmitted in this questionned ontract personnel who are occeding or related proceeding and operations of the Consistency of the Consistency of Authorized Of Title of Authorized Of	nis questionnai ubject to audit of Commission, of this proceeding adise. aire response acting in the of togs for which to Commission pu	re is complete and verification and its emplo g in any oth and through capacity of C this information	on by the Compyees and conter import-injustion out this procession in its content in its procession in its submitte	mission.  tract personn  try proceeding  teding may be  nployees, for o  ed, or in intern	el, to use th gs or review e used by th developing o nal audits an
ef and understand that the ns of this certification I of tion provided in this que, ed by the Commission on to wledge that information so sion, its employees, and co ning the records of this pro- ings relating to the progra- personnel will sign non-d	in supplied in response to the information submitted is surely also grant consent for the stionnaire and throughout the same or similar merchant ontract personnel who are occeeding or related proceedings and operations of the Conscioure agreements.	nis questionnai ubject to audit of Commission, of this proceeding adise. aire response acting in the of togs for which to Commission pu	re is complete and verification and its emplo g in any oth and through capacity of C this information	on by the Combyees and conter import-injustion out this procession endings. C. Appendings.	mission.  tract personn  tract personn  tract personn  tract personn  teding may be  tract personn  tract perso	el, to use th gs or review e used by th developing o nal audits an

#### PART I.—GENERAL INFORMATION

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 50 hours per response, including the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the questionnaire. Send comments regarding the accuracy of this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Office of Investigations, U.S. International Trade Commission, 500 E Street, SW, Washington, DC 20436.

I-1a. <u>OMB statistics.</u>--Please report below the actual number of hours required and the cost to your firm of preparing the reply to this questionnaire and completing the form.

Hours	Dollars

- I-1b. <u>OMB feedback</u>.--We are interested in any comments you may have for improving this questionnaire in general or the clarity of specific questions. Please attach such comments to your firm's response or send them to the above address.
- I-2. **Establishments covered.--**Provide the name and address of establishment(s) covered by this questionnaire (see page 3 of the instruction booklet for reporting guidelines). If your firm is publicly traded, please specify the stock exchange and trading symbol.
- I-3. **Position regarding continuation of order.--**Does your firm support or oppose continuation of the antidumping duty order currently in place for persulfates from the following country?

Country	Support	Oppose	Take no position
China			

# PART I.--GENERAL INFORMATION--Continued

	nershipIs your firm owned, in whole or in part, by any other firm?					
□ No	YesList	the following information.				
Firm name		Address	Extent of ownershing (e.g., percent of ownership)			
Related SU	BJECT importer	rs/exportersDoes your firm h	ave any related firms, either			
domestic or	foreign, that are e		from China into the United State			
☐ No	YesList	the following information.				
Firm name		Address	<u>Affiliation</u>			
Firm name		Address	Affiliation			
Firm name		Address	Affiliation			
Firm name		Address	Affiliation			
Related NO domestic or	foreign, that are e ted States or that a	oorters/exportersDoes your for any of the second	Affiliation  Firm have any related firms, either from countries other than China cates from countries other than China			
Related NO domestic or into the Uni	foreign, that are e ted States or that a d States?	oorters/exportersDoes your for any of the second	Firm have any related firms, either from countries other than China			

# PART I.--GENERAL INFORMATION--Continued

<b>Related producers.</b> Does your firm have any related firms, either domestic or foreign, that are engaged in the production of persulfates?					
☐ No	YesList the	e following information.			
Firm name		<u>Address</u>	<u>Affiliation</u>		
			request a copy of your company's		
	that describe, discuss  YesPlease	s, or analyze expected mark provide the requested docu			
documents t	that describe, discuss  YesPlease	s, or analyze expected mark	tet conditions for persulfates?  Imments. If you are not providing t		
documents t	that describe, discuss  YesPlease	s, or analyze expected mark provide the requested docu	tet conditions for persulfates?  Imments. If you are not providing t		
documents t	that describe, discuss  YesPlease	s, or analyze expected mark provide the requested docu	tet conditions for persulfates?  Imments. If you are not providing to		
documents t	that describe, discuss  YesPlease	s, or analyze expected mark provide the requested docu	tet conditions for persulfates?  Imments. If you are not providing t		

## PART II.--TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from Angela Newell (angela.newell@usitc.gov, 202-708-5409). **Supply all data requested on a <u>calendar-year</u> basis**.

Title Email Telephone	
Telephone	
Fax	
changes in relation to the production	icate whether your firm has experienced any of the for of persulfates since January 1, 2007.  (please describe)
(check as many as appropriate)	(pieuse uescribe)
plant openings	······
☐ plant closings	
relocations	······
- avmansions	
expansions	
acquisitions	······
Consolidations	
consondations	
prolonged shutdowns or	
production curtailments	······
production curtailments	

## PART II.--TRADE AND RELATED INFORMATION--Continued

<u>Anticipated changes in operations</u> Does your firm anticipate any changes in the character of your firm's operations or organization (as noted above) relating to the production of persulfates in the future?				
□ No	YesSupply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation that address this issue. Include in your response a specific projection of your firm's capacity to produce persulfates (in 1,000 pounds) for 2013 and 2014.			
anticipate any relating to the	changes in operations in the event the order is revokedWould your firm changes in the character of your firm's operations or organization (as noted above) production of persulfates in the future if the antidumping duty order on persulfates are to be revoked?			
□ No	YesSupply details as to the time, nature, and significance of such changes			

II-5.	<u>Same equipment, machinery, and workers.</u> —Has your firm since 2007 produced, or does your firm anticipate producing in the future, other products on the same equipment and machinery used in the production of persulfates and/or using the same production and related workers employed to produce persulfates?							nery	
	□ No □ `		pacity and	nation and I production					
	<u>Product</u>		Period Basis for allocation of employment data (ind						
									<u> </u>
			(Quantity	y in <i>1,000</i>	pounds)			lone	uom/
	Item		Calendar year				January- September		
0	II D	2007	2008	2009	2010	2011	2012	2012	2013
Produ	Il Production Capacity ction of: sulfates								
Oth	er product 1								
Oth	er product 2								
II-6.	Constraints on production capacity.	luction	Please des	scribe the	constraint	(s) that se	et the limit	t(s) on you	ır firm's
II-7.	<u>Production shifting.</u> Is your firm able to switch production between persulfates and other products in response to a relative change in the price of persulfates vis-à-vis the price of other products, using the same equipment and/or labor?								
	□ No □ Y	invo	olved in sv	vitching, a	products, and the mi production	nimum re	lative pri	ce change	

II-8. <u>Trade data.</u>--Report your firm's production capacity, production, shipments, inventories, and employment related to the production of persulfates in your firm's U.S. establishment(s) during the specified periods. (See definitions in the instruction booklet.)

	Quantity	(111 1,000		d value (in	φ1,000)		January 9	Santambai
léa-ma	2007	2000	1	lar year	2044	2042	<del> </del>	September
Average production capacity <sup>1</sup> (quantity) (A)	2007	2008	2009	2010	2011	2012	2012	2013
Beginning-of-period inventories (quantity) (B)								
Production (quantity) (C)								
U.S. shipments: Commercial shipments: quantity (D)								
value (E)								
Internal consumption: <sup>2</sup> quantity (F)								
value (G)								
Transfers to related firms: <sup>2</sup> quantity (H)								
value (I)								
Export shipments: <sup>3</sup> quantity (J)								
value (K)								
End-of-period inventories (quantity) (L)								
Channels of distribution: U.S. shipments to distributors (quantity) (M)								
U.S. shipments to end users (quantity) (N)								
Employment data: Average number of PRWs (number) (O)								
Hours worked by PRWs (1,000 hours) (P)								
Wages paid to PRWs (value) (Q)								
The production capacity (see weeks per year. Please des reported capacity (use additional particular)  1 The production capacity (see weeks per year. Please des reported capacity (use additional particular)	cribe the m	ethodology					hours pe	
<sup>2</sup> Internal consumption and tran uses a different basis for valuing the data using that basis for each of the	ese transade periods no	ctions, pleas oted above	se specify th	lued at fair nat basis (e.	market valu g., cost, co	ue. In the e	event that you	our firm de value

II-9	9.	Recond	iliation	of t	trade	data
------	----	--------	----------	------	-------	------

	(a)	Please note that the quantities reported in question II-8 should reconcile as follows in each period (i.e., in each column):						
		Reconciliation $B + C - D - F - H - C - D + F + H = M + N$	- J = L	Do these data reconcile?  Yes explain Yes explain Yes explain	☐ NoPlease			
	(b)	beginning-of-period	linventories	eported for end-of-period inventorie reported in the subsequent calendar f year 2008). Do these data reconci	r year (i.e., line L of			
		Yes.	NoPle	ase explain.				
II-10.	Transf	ers to related firms.	If your firi	m reported transfers to related firms	in question II-8,			
11-10.	venture market	please indicate the nature of the relationship between your firm and the related firms (e.g., joint venture, wholly owned subsidiary), whether the transfers were priced at market value or by a non-market formula, whether your firm retained marketing rights to all transfers, and whether the related firms also processed inputs from sources other than your firm.						

II-11. <u>Commercial shipments.</u>--What share of your firm's commercial shipments of persulfates was used in each of the following end use applications in 2012?

End use applications	Share of quantity of 2012 commercial shipments
Cosmetics and pharmaceuticals	%
Electronics (e.g. printed circuit board etchants)	%
Environmental remediation	%
Oil and gas recovery	%
Polymerization applications (plastics, synthetic rubber, adhesives)	%
Pool and spa supply	%
Pulp and paper	%
Textiles	%
Other:	100 %

	chasesOther that ary 1, 2007? (Se						ased persi	ulfates sin	ce
	No Y		ns differ	by source	, please el	aborate)		the quant	
Reas	sons:								
		(Quanti	ty in 1,000	pounds,	value <i>in \$</i> 1	1,000)			
			January- September						
	Item	2007	2008	2009	2010	2011	2012	2012	2013
PURCHASES IMPORTERS <sup>1</sup> PERSULFATE China: <i>quant</i>	OF ES FROM.—								
value									
All other co									
value									
PURCHASES DOMESTIC P quantity	FROM RODUCERS: <sup>2</sup>								
value									
PURCHASES SOURCES: quantity	FROM OTHER								
Value									
<sup>1</sup> Please list by source, plea	st the name of the i ase identify the sou	mporter(s) urce for eac	from which th listed su	your firm pplier.	purchased	this produ	ct. If your	firm's supp	liers differ
<sup>2</sup> Please lis	st the name of the	domestic pr	oducer(s)	from which	your firm p	ourchased	this produ	ct.	
	<b>production</b> Sin							agreemen	t (see
	No Y	esName	firm(s):						·
II-14. <b><u>FTZ</u></b>	Does your firn	n produce	persulfate	es in a fore	eign trade	zone (FT	°Z)?		
$\square$ N	√lo ∐ Y	esIdentif	fy FTZ(s)	:					

# PART II.--TRADE AND RELATED INFORMATION--Continued

II-15.	<u>Direct imports.</u> Since January 1, 2007, has your firm imported persulfates?
	☐ No ☐ Yes <u>COMPLETE AND RETURN A U.S. IMPORTERS'</u> <u>OUESTIONNAIRE</u>
II-16.	<b>Effect of order</b> Describe the significance of the existing antidumping duty order covering imports of persulfates from China in terms of its effect on your firm's production capacity, production, U.S. shipments, inventories, purchases, employment, revenues, costs, profits, cash flow, capital expenditures, research and development expenditures, and asset values. You may wish to compare your firm's operations before and after the imposition of the order.
II-17.	<u>Likely effect of revocation of order</u> Would your firm anticipate any changes in its production capacity, production, U.S. shipments, inventories, purchases, employment, revenues, costs, profits, cash flow, capital expenditures, research and development expenditures, or asset values relating to the production of persulfates in the future if the antidumping duty order on persulfate from China were to be revoked?
	No YesSupply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation for any trends or projections you may provide.

## PART III.--FINANCIAL INFORMATION

Address questions on this part of the questionnaire to Mary Klir (mary.klir@usitc.gov, 202-205-3247).

	Name		
_	Title		
_	Email		
_	Teleph	none	
_	Fax		
	Accou	nting sy	stemBriefly describe your firm's financial accounting system.
	A.		does your firm's fiscal year end (month and day)? firm's fiscal year changed during the data-collection period, explain below:
	B.1.		be the lowest level of operations (e.g., plant, division, company-wide) for which al statements are prepared that include persulfates:
	2.	Does y	rour firm prepare profit/loss statements for persulfates:
	3.	How o annual	ften did your firm (or parent company) prepare financial statements (including reports, 10Ks)? Please check relevant items below. dited, unaudited, annual reports, 10Ks, 10Qs, onthly, quarterly, semi-annually, annually
	4.	Accoun	nting basis: GAAP, cash, tax, or other comprehensive basis punting (specify)
		includir persulfa	The Commission may request that your company submit copies of its financial statements are internal profit-and-loss statements for the division or product group that includes ates, as well as those statements and worksheets used to compile data for your firm's innaire response.
			ng systemBriefly describe your firm's cost accounting system (e.g., standard cost, etc.).
	, 3		

III-5. Other products.--Please list any other products your firm produces in the facilities in which it

U.S. Producers' Questionnaire - Persulfates from China

## PART III.--FINANCIAL INFORMATION--Continued

<u>Products</u>			Share of sales
			%
			%
			%
			%
			%
Inputs from	related firmsIn the space presulfates that your firm put	provided below, ide	
Inputs from	related firmsIn the space p	provided below, ide rchases from related	entify the inputs used in the
Inputs from production of	related firmsIn the space p	provided below, ide rchases from related	entify the inputs used in the d parties.
Inputs from production of	related firmsIn the space p	provided below, ide rchases from related	entify the inputs used in the d parties.
Inputs from production of	related firmsIn the space p	provided below, ide rchases from related	entify the inputs used in the d parties.
Inputs from production of Input  Inputs from parties should costs reported associated production of Inputs from parties should costs reported associated production of Inputs from parties should costs reported associated production of Inputs from parties should costs reported associated production of Inputs from parties should costs reported associated production of Inputs from production of Inputs from production of Inputs from production of Inputs from parties should be a second production of Inputs from parties should be a second production of Inputs from parties should be a second production of Inputs from parties should be a second production of Inputs from production of Inputs from production of Inputs from parties should be a second production of Inputs from Inputs fr	related firmsIn the space p	tercompany profit of reported to the Corly reflect the related methods for determ	on inputs purchased from rel mmission in question III-10 d party's cost and not include nining and eliminating the
Inputs from production of  Input  Inputs from parties should costs reported associated production of the production of t	related firmsIn the space property persulfates that your firm pure related firms at costAll in the eliminated from the costs in question III-10 should on offit component). Reasonable	tercompany profit of reported to the Corly reflect the related methods for determ related parties are a	on inputs purchased from rel mmission in question III-10 d party's cost and not include nining and eliminating the acceptable.

#### PART III.--FINANCIAL INFORMATION--Continued

III-9. Nonrecurring items (charges and gains) included in reported persulfates financial results.—For each annual and interim period for which financial results are reported in question III-10, please specify all material (significant) nonrecurring items (charges and gains) in the schedule below, the specific table III-10 line item where the nonrecurring items are included, a brief description of the relevant nonrecurring items, and the associated values (in \$1,000), as reflected in table III-10; i.e., if an aggregate nonrecurring item has been allocated to table III-10, only the allocated value amount included in table III-10 should be reported in the schedule below. Note: The Commission's objective here is to gather information only on material (significant) nonrecurring items which impacted the reported persulfates financial results in table III-10.

			Fiscal yea	rs ended			Janu Septe	ary- mber
	2007	2008	2009	2010	2011	2012	2012	2013
Nonrecurring item: In this column please provide a brief description of each nonrecurring item and indicate the specific table III-10 line item where the nonrecurring item is included.	Nonrecurring item: In these columns please report the amount (in \$1,000) of the relevanonrecurring item reported in table III-10.					relevant		
1.								
2.								
3.								
4.								
5.								
6.								
7.								

### PART III.--FINANCIAL INFORMATION--Continued

III-10A. Operations on persulfates.—Report the revenue and related cost information requested below on the persulfates operations of your firm's U.S. establishment(s). Do not report resales of products. Note that internal consumption and transfers to related firms must be valued at fair market value and purchases from related firms must be at cost. Provide data for your firm's six most recently completed fiscal years, and for the specified interim periods.

	Quantity (in 1,	υυυ pounds) a	`			
			Fiscal year	s ended		
Item	2007	2008	2009	2010	2011	2012
Net sales quantities: <sup>3</sup> Commercial sales ("CS")						
Internal consumption ("IC")						
Transfers to related firms ("Transfers")						
Total net sales quantities	0	0	0	0	0	0
Net sales values: <sup>3</sup> Commercial sales						
Internal consumption						
Transfers to related firms						
Total net sales values	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold (COGS): <sup>4</sup> Raw materials						
Direct labor						
Other factory costs						
Total COGS	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit or (loss)	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general, and administrative (SG&A) expenses: Selling expenses						
General and administrative expenses						
Total SG&A expenses	0.0	0.0	0.0	0.0	0.0	0.0
Operating income (loss)	0.0	0.0	0.0	0.0	0.0	0.0
Other expenses and income: Interest expense						
All other expense items						
All other income items						
All other expenses/(income), net	0.0	0.0	0.0	0.0	0.0	0.0
Net income or (loss) before income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Depreciation/amortization included above						

<sup>&</sup>lt;sup>1</sup> Include only sales (whether domestic or export) and costs related to your <u>U.S. manufacturing operations</u>.

Note -- The table above contains calculations that will appear when you have entered data in the MS word form fields.

<sup>&</sup>lt;sup>2</sup> Please <u>eliminate any profits or (losses) on inputs from related firms</u> pursuant question III-8.

<sup>&</sup>lt;sup>3</sup> Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding shipment quantities and values reported in Part II of this questionnaire.

<sup>&</sup>lt;sup>4</sup> COGS should include costs associated with CS, IC, and Transfers, as well as export shipments in question II-8.

#### PART III.--FINANCIAL INFORMATION--Continued

### III-10A. Operations on persulfates. -- Continued

Item	(in 1,000) and value (in \$1,000)  January-September 2012	January-September 2013
Net sales quantities: <sup>3</sup>	Sandary-September 2012	January-September 2013
Commercial sales ("CS")		
Internal consumption ("IC")		
Transfers to related firms ("Transfers")		
Total net sales quantities	0	0
Net sales values: <sup>3</sup> Commercial sales		
Internal consumption		
Transfers to related firms		
Total net sales values	0.0	0.0
Cost of goods sold (COGS): <sup>4</sup> Raw materials		
Direct labor		
Other factory costs		
Total COGS	0.0	0.0
Gross profit or (loss)	0.0	0.0
Selling, general, and administrative (SG&A) expenses: Selling expenses		
General and administrative expenses		
Total SG&A expenses	0.0	0.0
Operating income (loss)	0.0	0.0
Other expenses and income: Interest expense		
All other expense items		
All other income items		
All other expenses/(income), net	0.0	0.0
Net income or (loss) before income taxes	0.0	0.0
Depreciation/amortization included above		

Note -- The table above contains calculations that will appear when you have entered data in the MS word form fields.

<sup>&</sup>lt;sup>1</sup> Include only sales (whether <u>domestic or export</u>) and costs related to your <u>U.S. manufacturing operations</u>.

<sup>2</sup> Please <u>eliminate any profits or (losses) on inputs from related firms</u> pursuant question III-8.

<sup>3</sup> Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding shipment quantities and values reported in Part II of this questionaire.

COGS should include costs associated with CS, IC, and Transfers, as well as export shipments in question II-8.

## PART III.--FINANCIAL INFORMATION--Continued

III-10B	sales quantities a loss)) have been fields return the	reconciliationThe calculable line items from question III-10A ( <i>i.e.</i> , total net and values, total COGS, gross profit (or loss), total SG&A, and net income (or calculated from the data submitted in the other line items. Do the calculated correct data according to your firm's financial records ignoring non-material may arise due to rounding?
	Yes N	ToIf the calculated fields do not show the correct data, please double check the feeder data for data entry errors and revise.
		Also, check signs accorded to the post operating income line items; the two expense line items should report positive numbers ( <i>i.e.</i> , expenses are positive and incomes or reversals are negativeinstances of the latter should be rare in those lines) while the income line item also in most instances should have its value be a positive number ( <i>i.e.</i> , income is positive, expenses or reversals are negative).
		If after reviewing and potentially revising the feeder data your firm has provided, the differences between your records and the calculated fields persist please identify and discuss the differences in the space below.

#### PART III.--FINANCIAL INFORMATION--Continued

III-11. <u>Asset values</u>.--Report the total assets (i.e., both current and long-term assets) associated with the production, warehousing, and sale of persulfates. If your firm does not maintain some or all of the specific asset information necessary to calculate total assets for persulfates in the normal course of business, please estimate this information based upon a method (such as production, sales, or costs) that is consistent with your firm's cost allocations in the previous question. Provide data as of the end of your firm's six most recently completed fiscal years.

**Note:** Total assets should reflect net assets after any accumulated depreciation and allowances deducted. Total assets should be allocated to the subject products if these assets are also related to other products. Please provide a brief explanation if there are any substantial changes in total asset value during the period; e.g., due to asset write-offs, revaluation, and major purchases.

Value ( <i>in \$1,000</i> )						
		Fiscal years ended				
Item	2007	2008	2009	2010	2011	2012
Total assets (net)						

III-12. <u>Capital expenditures and research and development expenses.</u>--Report your firm's capital expenditures and research and development expenses on persulfates. Provide data for your firm's six most recently completed fiscal years, and for the specified interim periods.

				Value (ii	n \$1,000)			
	Fiscal years ended January-S				September			
Item	2007	2008	2009	2010	2011	2012	2012	2013
Capital expenditures								
Research and development expenses								

III-13.	<u>Data consistency and reconciliation</u> Please indicate whether your firm's financial data for
	questions III-10, 11, and 12 are based on a calendar year or your firm's fiscal year:
	☐ Calendar year
	Fiscal year (specify)
	Please note the quantities and values remorted in quanties III 10 should recognile with the date
	Please note the quantities and values reported in question III-10 should reconcile with the data reported in question II-8 (including export shipments) as long as they are reported on the same calendar year basis.
	Do these data in question III-10 reconcile with data in question II-8?
	Yes NoPlease explain

#### PART IV.--PRICING AND MARKET FACTORS

Further information on this part of the questionnaire can be obtained from Aimee Larsen (202-205-3179, aimee.larsen@usitc.gov)

<u>Contact information</u>.-- Please identify the responsible individual and the manner by which Commission staff may contact that individual regarding the confidential information submitted in part IV.

Name	
Title	
Email	
Telephone	
Fax	

### **PRICE DATA**

IV-1. This question requests quarterly quantity and value data, f.o.b. your firm's U.S. point of shipment, for your firm's commercial shipments to unrelated distributors and end users since 2007 of the following products produced by your firm.

**Product 1.**—Potassium persulfates

**Product 2.—Ammonium persulfates** 

**Product 3.**—Sodium persulfates

Please note that total dollar values should be f.o.b., U.S. point of shipment and should not include U.S.-inland transportation costs. Total dollar values should reflect the *final net* amount paid to your firm (i.e., should be net of all deductions for discounts or rebates). Also, please report pricing separately for shipments to unrelated distributors and to unrelated end users. See instruction booklet.

## PART IV.--PRICING AND MARKET FACTORS--Continued

IV-1a. <u>Pricing data (shipments to distributors)</u>.--Report below the quarterly price data<sup>1</sup> for pricing products<sup>2</sup> produced and sold by your firm to unrelated <u>distributors</u>.

Report data in actual pounds and actual dollars (not 1,000s).

			nds, value in do		•	
	Product 1 Product 2				Product 3	
Period of shipment	Quantity	Value	Quantity	Value	Quantity	Value
2007:						
January-March			+		+	
April-June						
July-September						
October-December						
2008: January-March						
April-June						
July-September						
October-December						
2009: January-March						
April-June			1			
July-September			1			
October-December			1			
2010:			1			
January-March						
April-June						
July-September						
October-December						
2011:						
January-March						
April-June						
July-September						
October-December						
2012: January-March						
April-June						
July-September						
October-December						
2013:						
January-March						
April-June						
July-September						
Net values (i.e., gross returned goods), f.o.b. your     Pricing product defini  NoteIf your firm's product	r firm's U.S. point itions are provide	t of shipment. ed on the first p	page of Part IV.			
product, provide a descripti	ion of the produc	t. Also, pleas	e explain any an	omalies in yo		
Product 1:						
Product 2:						
Product 3:						

## PART IV.--PRICING AND MARKET FACTORS--Continued

IV-1b. <u>Pricing data (shipments to end users).</u>--Report below the quarterly price data<sup>1</sup> for pricing products<sup>2</sup> produced and sold by your firm to unrelated <u>end users</u>.

Report data in actual pounds and actual dollars (not 1,000s).

			nds, value in d			
	Prod		Pro	duct 2	Prod	uct 3
Period of shipment	Quantity	Value	Quantity	Value	Quantity	Value
2007:						
January-March						
April-June						
July-September						
October-December						
2008:						
January-March						
April-June						
July-September						
October-December						
2009:						
January-March						
April-June						
July-September						
October-December						
2010:						
January-March						
April-June						
July-September						
October-December						
2011:						
January-March						
April-June						
July-September						
October-December						
2012:						
January-March						
April-June						
July-September						
October-December						
2013:						
January-March						
April-June						
July-September						
<sup>1</sup> Net values (i.e., gross returned goods), f.o.b. your <sup>2</sup> Pricing product defini	firm's U.S. poin	t of shipment.			id freight, and the	e value of
NoteIf your firm's product product, provide a description						
Product 1:						
Product 2:						
Product 3:						

#### PART IV.--PRICING AND MARKET FACTORS--Continued

IV-2. <u>Price setting.--</u> How does your firm determine the prices that it charges for sales of persulfates (*check all that apply*)? If your firm issues price lists, please submit sample pages of a recent list.

Transaction by transaction	Contracts	Set price lists	Other	If other, describe

IV-3. <u>Discount policy.--</u> Please indicate and describe your firm's discount policies (*check all that apply*).

Quantity discounts	Annual total volume discounts	No discount policy	Other	Describe

### IV-4. Pricing terms for persulfates.--

(a) What are your firm's typical sales terms for its U.S.-produced persulfates?

Net 30 days	Net 60 days	2/10 net 30 days	Other	Other (specify)

(b) On what basis are your firm's prices of domestic persulfates usually quoted (check one)?

Delivered	F.o.b.	If f.o.b., specify point

IV-5. <u>Contract versus spot.--</u> Approximately what share of your firm's sales of its U.S.-produced persulfates in 2012 was on a (1) long-term contract basis, (2) short-term contract basis, and (3) spot sales basis?

	Type of sale			
	Long-term contracts (multiple deliveries for more than 12 months)	Short-term contracts (multiple deliveries up to and including 12 months)	Spot sales (for a single delivery)	Total
Share of your 2012 sales	%	%	%	=100%

#### PART IV.--PRICING AND MARKET FACTORS--Continued

IV-6. <u>Contract provisions.</u>— Please fill out the table with respect to provisions of your firm's typical sales contracts for persulfates (or check "not applicable" if your firm does not sell on a long-term and/or short-term contract basis).

Typical sales contract provisions	Item	Short-term contracts (multiple deliveries up to and including 12 months)	Long-term contracts (multiple deliveries for more than 12 months)
Average contract duration	Number of days		
Price renegotiation (during the	Yes		
contract period)	No		
	Quantity		
Fixed quantity and/or price	Price		
	Both		
Most or release provision	Yes		
Meet or release provision	No		
Not applicable			

IV-7. <u>Lead times.--</u>What is the average lead time between a customer's order and the date of delivery for your firm's sales of your firm's U.S.-produced persulfates?

Source	Share of 2012 sales	Lead time (days)
From inventory	%	
Produced to order	%	
Total	100 %	

#### IV-8. Shipping information.--

(a)	What is the approximate percentage of the total delivered cost of persulfates that is
	accounted for by U.S. inland transportation costs? %

- (b) Who generally arranges the transportation to your firm's customers' locations?

  your firm purchaser (check one)
- (c) Indicate the approximate percentage of your firm's sales of persulfates that are delivered the following distances from your firm's production facility.

Distance from production facility	Share	
Within 100 miles		%
101 to 1,000 miles		%
Over 1,000 miles		%
Total	100	%

#### PART IV.--PRICING AND MARKET FACTORS--Continued

IV-9. <u>Geographical shipments.--</u> What is the geographic market area in the United States served by your firm's persulfates? (check all that apply)

Geographic area	if applicable
NortheastCT, ME, MA, NH, NJ, NY, PA, RI, and VT.	
MidwestIL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI.	
SoutheastAL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV.	
Central SouthwestAR, LA, OK, and TX.	
MountainsAZ, CO, ID, MT, NV, NM, UT, and WY.	
Pacific CoastCA, OR, and WA.	
<b>Other</b> .—All other markets in the United States not previously listed, including AK, HI, PR, and VI, among others.	

IV-10. **End uses.--**List the end uses of the persulfates that your firm manufactures. For each end-use product, what percentage of the <u>total cost</u> is accounted for by persulfates and other inputs?

	Share of total cost account		
End use product	Persulfates (percent)	Other inputs (percent)	Total
	%	%	100%
	%	%	100%
	%	%	100%

IV-11. <u>Changes in end uses.--</u>Have there been any changes in the end uses of persulfates since 2007? Do you anticipate any future changes?

Changes in end uses	No	Yes	Explain
Changes since 2007			
Anticipated changes			

# PART IV.--PRICING AND MARKET FACTORS--Continued

			End use in which this			Have changes in the price of this substitute affected the price for persulfates?			
	Substitute			substitute is used			Yes	Explanation	
i.									
	Changes in substitutes		No	Yes				Explain	
-13.								the number or types of products that sipate any future changes?	
	Substitutes Changes since		NO	res				Explain	
	Changes	since	11 1						
	Changes 2007	since							
<sup>7</sup> -14.	Anticipate changes	ed							
<sup>7</sup> -14.	Anticipate changes  Raw mate  (a) To	erials			changes in the price since 2007?	es of 1	raw m	naterials affected your firm's selling	
<i>7</i> -14.	Anticipate changes  Raw mate  (a) To	erials				es of 1	aw m	naterials affected your firm's selling	
V-14.	Anticipate changes  Raw mate  (a) To pr	erials o what exices for	persu	ılfates	since 2007?			naterials affected your firm's selling rial costs in the foreseeable future?	
V-14.	Anticipate changes  Raw mate  (a) To pr	erials o what exices for	persu	ate cha	since 2007?	's raw	mate		

## PART IV.--PRICING AND MARKET FACTORS--Continued

IV-15.	supply (e.g	g., change n capacity n opportu	es in availab and/or met nities) that a	<b>upply</b> Have any changes occurred in any other factors affecting ility or prices of energy or labor; transportation conditions; hods of production; technology; export markets; or alternative affected the availability of U.Sproduced persulfates in the U.S.
	No	l		se note the time period(s) of any such changes, the factors(s) and the impact such changes had on your firm's shipment and prices.
IV-16.				<u>roduced</u> )Do you anticipate any changes in terms of the ersulfates in the U.S. market in the future?
	Increase	No change	Decrease	If you anticipate changes in supply, please explain.
IV-17.				<b>bject)</b> Has the availability of <u>NONSUBJECT</u> persulfates (i.e., tries other than China) changed since 2007?
	No	Yes	lf yes, pleas	se explain.
IV-18.	U.S. mark other sales	et and alt arranger	ernative counents, or oth	how easily your firm can shift its sales of persulfates between the antry markets. In your discussion, please describe any contracts, ner constraints that would prevent or retard your firm from shifting and alternative country markets within a 12-month period.

### PART IV.--PRICING AND MARKET FACTORS--Continued

IV-19.	<b>Product changes</b> Have there been any s	significant changes i	in the product range,	product mix,
	or marketing of persulfates since 2007? D	o you anticipate any	y future changes?	

Changes in product range,			
product mix, or marketing	No	Yes	Explain
Changes since 2007			
Anticipated changes			

IV-20. <u>Demand trends.--</u> Indicate how demand within the United States and outside of the United States (if known) for persulfates has changed since January 1, 2007, and how you anticipate demand will change in the future. Explain any trends and describe the principal factors that have affected, and that you anticipate will affect, these changes in demand.

Market	Overall increase	No change	Overall decrease	Fluctuate with no clear trend	Explanation and factors		
Demand since 2007							
Within the United States							
Outside the United States							
	Anticipated future demand						
Within the United States							
Outside the United States							

## PART IV.--PRICING AND MARKET FACTORS--Continued

IV-21.	Condition	Conditions of competition						
	(a) Is the persulfates market subject to business cycles (other than general economy-wide conditions) and/or other conditions of competition distinctive to persulfates?							
	<ul> <li>No (skip to question IV-22).</li> <li>Yes-Business cycles (e.g. seasonal business).</li> <li>Yes-Other distinctive conditions of competition.</li> </ul>							
	If yes, de	escribe be	low.					
	Busine	ss cycles	5					
	Other c	onditions petition	s					
			ere been any changes in the business cycles or conditions of competition for anuary 1, 2007?					
	No	Yes	If yes, please describe.					
IV-22.	<u>Price comparisons.</u> Please compare market prices of persulfates in U.S. and non-U.S. markets, if known. Provide specific information as to time periods and regions for any price comparisons.							
IV-23. IV-24.	Market studiesPlease provide as a separate attachment to this request any studies, surveys, etc. that you are aware of that quantify and/or otherwise discuss persulfates supply (including production capacity and capacity utilization) and demand in (1) the United States, (2) each of the other major producing/consuming countries, including China, and (3) the world as a whole. Of particular interest is such data from 2007 to the present and forecasts for the future.  Barriers to tradeAre your firm's exports of persulfates subject to any tariff or non-tariff barriers to trade in other countries?							
	No	Yes	If yes, please list the countries and describe any such barriers and any significant changes in such barriers that have occurred since 2007, or that are expected to occur in the future.					

#### PART IV.--PRICING AND MARKET FACTORS--Continued

IV-25. <u>Interchangeability</u>.--Are persulfates produced in the United States and in other countries interchangeable (*i.e.*, can they physically be used in the same applications)?

Please indicate A, F, S, N, or 0 in the table below:

A = the products from a specified country-pair are *always* interchangeable

F = the products are *frequently* interchangeable

S = the products are *sometimes* interchangeable

N = the products are *never* interchangeable

0 = no familiarity with products from a specified country-pair

Country-pair	China	Other countries
United States		
China		
	r-pair producing persulfates that is <i>some</i> ors that limit or preclude interchangeabl	etimes or never interchangeable, please e use:

#### PART IV.--PRICING AND MARKET FACTORS--Continued

IV-26. <u>Factors other than price</u>.--Are differences other than price (i.e., quality, availability, transportation network, product range, technical support, etc.) between persulfates produced in the United States and in other countries a significant factor in your firm's sales of the products?

Please indicate A, F, S, N, or 0 in the table below:

A = such differences are *always* significant

F = such differences are *frequently* significant

S = such differences are *sometimes* significant

N =such differences are *never* significant

0 = no familiarity with products from a specified country-pair

Country-pair China Other countries  United States  China  For any country-pair for which factors other than price always or frequently are a significant factor in your firm's sales of persulfates, identify the country-pair and report the advantages or disadvantages imparted by such factors:			
China  For any country-pair for which factors other than price <i>always</i> or <i>frequently</i> are a significant factor in your firm's sales of persulfates, identify the country-pair and report the advantages or	Country-pair	China	Other countries
For any country-pair for which factors other than price <i>always</i> or <i>frequently</i> are a significant factor in your firm's sales of persulfates, identify the country-pair and report the advantages or	United States		
factor in your firm's sales of persulfates, identify the country-pair and report the advantages or	China		
	factor in your fir	m's sales of persulfates, identify the co	